高级搜索

新辅助化疗对进展期胃癌手术并发症的影响

叶建新, 刘声源, 庄金福

叶建新, 刘声源, 庄金福. 新辅助化疗对进展期胃癌手术并发症的影响[J]. 肿瘤防治研究, 2014, 41(09): 1026-1030. DOI: 10.3971/j.issn.1000-8578.2014.09.015
引用本文: 叶建新, 刘声源, 庄金福. 新辅助化疗对进展期胃癌手术并发症的影响[J]. 肿瘤防治研究, 2014, 41(09): 1026-1030. DOI: 10.3971/j.issn.1000-8578.2014.09.015
YE Jianxin, LIU Shengyuan, ZHUANG Jinfu. Influence of Neoadjuvant Chemotherapy on Operative Complications of Advanced Gastric Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(09): 1026-1030. DOI: 10.3971/j.issn.1000-8578.2014.09.015
Citation: YE Jianxin, LIU Shengyuan, ZHUANG Jinfu. Influence of Neoadjuvant Chemotherapy on Operative Complications of Advanced Gastric Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(09): 1026-1030. DOI: 10.3971/j.issn.1000-8578.2014.09.015

新辅助化疗对进展期胃癌手术并发症的影响

详细信息
    作者简介:

    叶建新(1966-),男,博士,主任医师,主要从事胃肠及胰腺肿瘤基础与临床研究

  • 中图分类号: R735.2

Influence of Neoadjuvant Chemotherapy on Operative Complications of Advanced Gastric Carcinoma

  • 摘要: 目的 探讨新辅助化疗对进展期胃癌手术并发症的影响。方法 随机数字表法将2009年9月—2013年7月在福建医科大学附属第一医院胃肠外科接受治疗的145例进展期胃癌患者,分为新辅助化疗组(62例)和直接手术组(83例)。比较两组病例术后并发症发生情况。结果 两组病例术前一般情况比较差异无统计学意义(P>0.05)。两组术后主要并发症发生率的差异无统计学意义(P>0.05)。化疗组术后第7天白细胞水平显著高于术前及同期常规手术组,两组比较差异有统计学意义(P <0.05)。新辅助化疗组的手术根治率高于常规手术组,两组比较差异有统计学意义(P<0.05)。结论 新辅助化疗不会增加手术并发症的发生率,并可提高手术根治率。

     

    Abstract: Objective To explore the effects of neoadjuvant chemotherapy on the operative complications of advanced gastric carcinoma. Methods According to random number table method, 145 patients with advanced gastric carcinoma hospitalized in the Gastrointestinal Surgery Department of The First Affiliated Hospital of Fujian Medical University from Sep 2009 to Jul 2013 were randomly divided into two groups, one group (62 cases) received neoadjuvant chemotherapy and surgery, and the other group (83 cases) received conventional surgery. Operative complications in two groups were compared. Results Between the two groups, the differences of general conditions before operations and incidence rate of main operative complications had no statistical significance(P>0.05). Postoperative white blood cells of neoadjuvant chemotherapy group after 7 days were significantly higher than those of preoperative and corresponding period of conventional surgery group, with statistically significant difference(P<0.05). Operation cure rate of neoadjuvant chemotherapy group was higher than that of conventional surgery group, with statistical significance(P<0.05). Conclusion Neoadjuvant chemotherapy is helpful to improve operation cure rate without increasing the risk of postoperative complications.

     

  • [1] Chinese medical association branch of laparoscopic and endoscopic surgery group. Operational guidelines of laparoscopic gastric malignancy(2007 version)[J].Wai Ke Li Lun Yu Shi Jian,2007,12(6):610-4.[中华医学会外科分会腹腔镜与内镜外科 学组.腹腔镜胃恶性肿瘤手术操作指南(2007版)[J]. 外科理论与 实践,2007,12(6):610-4.]
    [2] Sun W,Haller DG. Recent advances in the treatment of gastgic cancer[J]. Drugs,2001,61(11):1545-51.
    [3] Wilke H, Preusser P, Fink U, et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide,doxorubicin, and cisplatin[J]. J Clin Oncol,1989, 7(9): 1318-26.
    [4] Cunningham D, Allum WH,Stenning SP,et al. Perioperative c h emo t h e r a p y v e r s u s s u rg e r y a l o n e f o r r e s e c t a b l e gastroesophageal cancer[J]. N Engl J Med,2006,355(1):11-20.
    [5] Lowy AM,Mansfield PF,Leach SD,et al.Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer[J]. Ann Surg,1999,229(3):303-8.
    [6] Ji JF.Gastrointestinal tumor of neoadjuvant chemotherapy[J]. Zhongguo Shi Yong Wai Ke Za Zhi,2005,5(25):261-3.[季加孚.胃肠 道肿瘤的新辅助化疗[J].中国实用外科杂志,2005,5(25):261-3.]
    [7] Sano T,Sasako M,Yamamoto S,et al.Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group Study 9501[J]. J Clin Oncol,2004,22(14):2767-73.
    [8] Park DJ,Lee HJ,Kim HH,et al.Predictors of operative morbidity and mortality in gastric cancer surgery[J].Br J Surg,2005,92(9):10 99 -102.
    [9] Lin XT,Chen LC,Zheng SR,et al. Factors for gastroparesis after distal subtotal gastrectomy:binary logistic regression analysis[J]. Fujian Yi Ke Da Xue Xue Bao,2009,43(6):507-9.[林小提,陈路川, 郑赛榕,等.胃癌远端胃术后残胃胃瘫影响因素Logistic回归分 析[J] 福建医科大学学报,2009,43(6):507-9.]
    [10] Biffi R,Fazio N,Luca F,et al.Surgical outcome after docetaxelbased neoadjuvant chemotherapy in locally-advanced gastric cancer[J].World J Gastroenterol,2010,16(7):868-74.
    [11] Schuhmacher C,Gretschel S,Lordick F,et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954[J].J Clin Oncol,2010,28(35):5210-8.
    [12] Fujitani K,Ajani JA,Crane CH,et al.Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction[J]. Ann Surg Oncol,2007,14(7):2010-7.
    [13] Valenti V,Hernandez-Lizoafn JL,Beorlegui MC,et al.Mor bidity,mortality,and pathological response in patients with gastric cancer preoperatively treated with chemotherapy or chemoradiotherapy[J].J Surg Oncol,2011,104(2):124-9.
计量
  • 文章访问数:  1142
  • HTML全文浏览量:  297
  • PDF下载量:  607
  • 被引次数: 0
出版历程
  • 刊出日期:  2014-09-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭